Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus chemotherapy for unresectable advanced desmoid tumors
NCT05490667Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anlotinib in desmoid tumor, sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
desmoid tumor
Beyond the preview
Go deeper on NCT05490667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490667.